Interstitial Cystitis - Drug Pipeline Landscape, 2023

Interstitial Cystitis - Drug Pipeline Landscape, 2023

Interstitial cystitis also called painful bladder syndrome, is a chronic bladder problem usually related to bladder pressure and pain, with irregular pain in either the lower abdomen, pelvis or lower back. There are two types of interstitial cystitis: non-ulcerative interstitial cystitis and Ulcerative interstitial cystitis.

Causes of interstitial cystitis include age, chronic pain disorders, such as irritable bowel syndrome or fibromyalgia, and some of the factors contributing to interstitial cystitis are a defect of the epithelium layer of the bladder and leaking epithelium allows toxic agents in urine to irritate the bladder wall.

Interstitial cystitis is prone to affect women more than men. Common symptoms of interstitial cystitis include bladder pain and pressure, frequent urination, pain in the vagina or vulva in the case of women, and pain in the scrotum or testicles in the case of men.

Interstitial cystitis is diagnosed by Urine analysis and cystoscopy to look inside the urethra and bladder.

Interstitial cystitis is treated by non-steroidal anti-inflammatory drugs, antidepressants, and antihistamines.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Interstitial Cystitis treatment such as Botox, SI-722, MR-MC-01 and others. Key players involved in the development of therapies to treat Interstitial Cystitis are Abbvie, Dompe Farmaceutici SpA, Imbrium Therapeutics LP, Mirae Cell Bio, Seikagaku Corporation and others. Two drugs are under clinical-stage Phase II clinical trials and three drug are in Phase I clinical trials and some other drugs are under preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Interstitial Cystitis - Drug Pipeline Landscape, 2023 report provides an overview of the Interstitial Cystitis pipeline drugs. This report covers detailed insights on Interstitial Cystitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Interstitial Cystitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Interstitial Cystitis - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Interstitial Cystitis
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Interstitial Cystitis - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2022
3.3 Products under Development by Companies, 2022
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.4 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs – Phase II
5.1.1 Botox
5.1.2 SI-722
5.2 Clinical Stage Drugs – Phase I
5.2.1 IMB-150
5.2.2 IW-3300
5.2.3 MR-MC-01
5.3 Clinical Stage Drugs – Preclinical
5.2.4 DF2755A
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Abbvie
9.2 Dompe Farmaceutici SpA
9.3 Imbrium Therapeutics LP
9.4 Ironwood Pharmaceuticals
9.5 Mirae Cell Bio
9.6 Seikagaku Corporation
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1.1 Number of Products under Development by Interstitial Cystitis
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details -Botox/Abbvie
Table 2.2 Clinical Trial Details -SI-722/Seikagaku Corporation
Table 2.3 Clinical Trial Details -MR-MC-01/Mirae Cell Bio
Table 3.1 Key Regulatory Designations
Table 4.1 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1.1 Number of Products under Development for Interstitial Cystitis, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Interstitial Cystitis, 2023
Figure 1.3 Products by Top 5 Mechanism of Action for Interstitial Cystitis, 2023
Figure 1.4 Products by Top 5 Molecule Type for Interstitial Cystitis, 2023
Figure 1.5 Products by Top 5 Route of Administration for Interstitial Cystitis, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings